Novartis

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab).

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

The CD20 monoclonal antibody (mAb) was originally developed by Danish biotech company Genmab, and subsequently developed and marketed worldwide by Novartis under a licence agreement. ... According to Genmab, Kesimpta is the first B-cell therapy that can

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

To support the planned rollout of its COVID-19 jab, CureVac has signed a number of strategic agreements, including with Novartis and Bayer. ... Novartis plans to manufacture the mRNA and bulk drug product of CureVac's CVnCoV for up to 50 million doses by

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19. ... Novartis has signed an initial agreement with Roche to help produce its repurposed COVID-19 treatment Actemra/RoActemra.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]